{"success":true,"data":{"pressRelease":{"id":"59104","rtpr_id":"nACSDLYCBa","ticker":"ATRA","exchange":"NASDAQ","all_tickers":["ATRA"],"title":"Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation","author":"ACCESSWIRE","published_at":"2026-06-09T15:00:03.950Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June\n9, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims\non behalf of purchasers of Atara Biotherapeutics, Inc. (\"Atara\" or \"the\nCompany\") (NASDAQ:ATRA). Investors who purchased Atara securities prior to May\n20, 2024, and continue to hold to the present, are encouraged to obtain\nadditional information and assist the investigation by visiting the firm's\nsite: bgandg.com/ATRA.\n(https://bgandg.com/ATRA/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ATRA)\n(https://app.accessnewswire.com/imagelibrary/5438079c-d605-4919-9cb8-1427d9986837/image.png)\nAtara Investigation Details\n\nThe investigation concerns whether Atara and certain of its officers and/or\ndirectors have engaged in corporate wrongdoing.\n\nWhat's Next for Atara Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nAtara shares, you can assist this investigation by visiting the firm's site:\nbgandg.com/ATRA\n(https://bgandg.com/ATRA/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ATRA).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to Atara Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Atara Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/atara-biotherapeutics-inc.-atra-investigation-bronstein-gewirtz-1170741)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSDLYCBa","title":"Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation","author":"ACCESSWIRE","ticker":"ATRA","created":"2026-06-09T15:00:03.950Z","tickers":["ATRA"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June\n9, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims\non behalf of purchasers of Atara Biotherapeutics, Inc. (\"Atara\" or \"the\nCompany\") (NASDAQ:ATRA). Investors who purchased Atara securities prior to May\n20, 2024, and continue to hold to the present, are encouraged to obtain\nadditional information and assist the investigation by visiting the firm's\nsite: bgandg.com/ATRA.\n(https://bgandg.com/ATRA/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ATRA)\n(https://app.accessnewswire.com/imagelibrary/5438079c-d605-4919-9cb8-1427d9986837/image.png)\nAtara Investigation Details\n\nThe investigation concerns whether Atara and certain of its officers and/or\ndirectors have engaged in corporate wrongdoing.\n\nWhat's Next for Atara Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nAtara shares, you can assist this investigation by visiting the firm's site:\nbgandg.com/ATRA\n(https://bgandg.com/ATRA/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ATRA).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to Atara Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Atara Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/atara-biotherapeutics-inc.-atra-investigation-bronstein-gewirtz-1170741)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-06-09T15:00:03.997299745Z","server_sent_at_ms":1781017203997},"received_at":"2026-06-09T15:00:04.067Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/atara-biotherapeutics-inc.-atra-investigation-bronstein-gewirtz-1170741"},"analysis":{"id":"48535","press_release_id":"59104","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics securities.\n\nThe investigation concerns whether Atara and certain of its officers and/or directors have engaged in corporate wrongdoing, targeting investors who purchased shares prior to May 20, 2024.\n\nThis release is a contingency-fee solicitation encouraging shareholders to contact the firm; no court certification or settlement has been announced.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"client relations manager"}],"products":[],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"Atara Biotherapeutics, Inc.","ticker":"ATRA"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bronstein, Gewirtz & Grossman, LLC. No new disclosure from the issuer; no certified class, no settlement. Boilerplate investigation announcement."},"tickerRelevance":{"others":[],"primary":"ATRA"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics securities.\n\nThe investigation concerns whether Atara and certain of its officers and/or directors have engaged in corporate wrongdoing, targeting investors who purchased shares prior to May 20, 2024.\n\nThis release is a contingency-fee solicitation encouraging shareholders to contact the firm; no court certification or settlement has been announced.","key_figures":{},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"client relations manager"}],"products":[],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"Atara Biotherapeutics, Inc.","ticker":"ATRA"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-09T15:09:29.539Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":92313,"modelName":"george-droid-qwen-72b"}}